J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671
Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
0
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-ZC-FT-376965
Apr 10, 2019 - Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
0
Why Eli Lilly (LLY) is a Great Dividend Stock Right Now
http://www.zacks.com/stock/news/376824/why-eli-lilly-lly-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-376824
Apr 10, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
0
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |
| SNY | Sanofi | NYSE | $43.75 | $109.14B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| BMY | Bristol-Myers Squibb Company | NYSE | $61.3 | $100.03B |
| GSK | GlaxoSmithKline PLC | NYSE | $39.21 | $97.25B |